| pubmed-article:10972629 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10972629 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:10972629 | lifeskim:mentions | umls-concept:C0028621 | lld:lifeskim |
| pubmed-article:10972629 | lifeskim:mentions | umls-concept:C1096176 | lld:lifeskim |
| pubmed-article:10972629 | lifeskim:mentions | umls-concept:C1273870 | lld:lifeskim |
| pubmed-article:10972629 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:10972629 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:10972629 | pubmed:dateCreated | 2000-12-11 | lld:pubmed |
| pubmed-article:10972629 | pubmed:abstractText | This article reviews the clinical manifestations of mitochondrial toxicity associated with the use of nucleoside analog reverse transcriptase inhibitors (NRTIs) and outlines strategies to manage these sequelae. | lld:pubmed |
| pubmed-article:10972629 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10972629 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10972629 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10972629 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10972629 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10972629 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10972629 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:10972629 | pubmed:issn | 0149-2918 | lld:pubmed |
| pubmed-article:10972629 | pubmed:author | pubmed-author:MoyleGG | lld:pubmed |
| pubmed-article:10972629 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10972629 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:10972629 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10972629 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10972629 | pubmed:pagination | 911-36; discussion 898 | lld:pubmed |
| pubmed-article:10972629 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10972629 | pubmed:meshHeading | pubmed-meshheading:10972629... | lld:pubmed |
| pubmed-article:10972629 | pubmed:meshHeading | pubmed-meshheading:10972629... | lld:pubmed |
| pubmed-article:10972629 | pubmed:meshHeading | pubmed-meshheading:10972629... | lld:pubmed |
| pubmed-article:10972629 | pubmed:meshHeading | pubmed-meshheading:10972629... | lld:pubmed |
| pubmed-article:10972629 | pubmed:meshHeading | pubmed-meshheading:10972629... | lld:pubmed |
| pubmed-article:10972629 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10972629 | pubmed:articleTitle | Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. | lld:pubmed |
| pubmed-article:10972629 | pubmed:affiliation | Chelsea and Westminster Hospital, London, United Kingdom. gm@moyleg.demon.co.uk | lld:pubmed |
| pubmed-article:10972629 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10972629 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10972629 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10972629 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10972629 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10972629 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10972629 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10972629 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10972629 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10972629 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10972629 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10972629 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10972629 | lld:pubmed |
